Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 lumicitabine dose-ranging trial in hospitalized infants and young children with RSV infection
MOH_2018-04-14_001957Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumicitabine in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Dose-response effect on antiviral activity. Started Nov 2017; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on MOH_2018-04-14_001957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-14_001957.